https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11434
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11434
No pharmaceutical opinion available for this interaction.
Cations by chelation may reduce the absorption of Dolutegravir.
Possible decrease of clinical efficacy.
Tivicay, Triumeq or Dovato : administer 2 hours before or 6 hours after the antacid.
Juluca : Administer 4 hours before or 6 hours after the antacid.
Monitor for clinical efficacy.
–
–
Avoid association, if possible.
For Tivicay, Triumeq or Dovato : H2 receptor antagonists or proton pump inhibitors. For Juluca : H2 receptor antagonists administered 4 hours or 12 hours after Juluca. Proton Pump Inhibitors contraindicated.
–
Dolutegravir plasma level
CD4+
Viral load HIV
| Reference number |
|---|
| # patients |
| HIV |
| Dose |
| Frequency |
| AUC |
| Cmax |
| Cmin |
| 2824 | 2824 |
|---|---|
| 16 | 16 |
| - | - |
| 50 mg * | 50 mg † |
| x 1 | x 1 |
| - 74% | - 26% |
| - 72% | - 18% |
| - 74% | - 30% |
| 2824 | 2824 |
|---|---|
| 16 | 16 |
| - | - |
| 20 ml | 20 ml |
Ref #2824 : * Dolutegravir administered
simultaneously with the antacid.
† Dolutegravir administered2 hours before the antacid.
Dolutegravir should not be taken together with Maalox or any antacids containing significant amounts of metal cations. Administration of antacid 2 hours after dolutegravir attenuated the impact of antacid. The mean C24h of 0.56μg/mL with a 2 hour separation of antacid represents a value of 5.6-fold above the PA-IC90. It is recommended that dolutegravir should be administered 2 hours before or 6 hours after antacids.